Geneticure

Curated by Signal

Pharmacogenomic tests for cardiovascular drug response.

Overview

Geneticure develops pharmacogenomic tests for cardiovascular drug response. Its platform technology is a proprietary gene panel that evaluates a set of biomarkers indicated in maintaining blood pressure. This is then correlated to response to commonly prescribed hypertension drugs: diuretics, vasodilators or beta blockers. Clinicans can send a patient buccal swab and access results within two weeks using a secure online portal.

Key facts

Founded: 2012
Headquarters: Minnetonka, United States
Stage: Sign up to view
Industry: Life Sciences Technology

Business model

2 products and services: Sign up to view

More on Vanberra Signal

Members only

Business overviewCore metrics and financials PeopleLeadership and key people Similar companiesPeers and competitors Deep AnalysisAI-generated strategic report

Competitors & similar companies

More Life Sciences Technology companies

Nebula Genomics
Developer of DNA Sequencing technology for personal genomics
Life Sciences TechnologySan Francisco, United States
Cardiac Genetic Testing
Provider of a research facility in cardiovascular genetics
Life Sciences TechnologyNorth Babylon, United States
Immuneering Corporation
Provider of an AI-enabled bioinformatics platform for clinical solutions
Life Sciences TechnologyCambridge, United States

About Geneticure

What does Geneticure do?

Geneticure develops pharmacogenomic tests for cardiovascular drug response.

Where is Geneticure headquartered?

Geneticure is headquartered in Minnetonka, United States.

When was Geneticure founded?

Geneticure was founded in 2012.

Which sector is Geneticure in?

Geneticure operates in Life Sciences Technology.

Who are Geneticure's competitors?

Companies similar to Geneticure include Nebula Genomics, Cardiac Genetic Testing, and Immuneering Corporation.